P300 histone acetylase inhibitor

Details P300 histone acetylase inhibitor P300 histone acetylase inhibitor

2002-08-13

2010-11-16

Goddard, Laura B (Department: 1642)

Organic compounds -- part of the class 532-570 series

Organic compounds

Carbohydrates or derivatives

C536S024330

Reexamination Certificate

active

07834169

ABSTRACT:
An inhibitor of histone acetyltransferase p300 was isolated from human cDNA library and identified as a nuclear protein composed of 855 amino acid residues. It binds to the cysteine/histidine-rich region of p300, thereby inhibiting the transcriptional activation by p300. It also inhibits the transcription activity of p53, with p300 functioning as a coactivator, and inhibits the discontinuance of cell cycle that relies on p53.

REFERENCES:
patent: 6551795 (2003-04-01), Rubenfield et al.
patent: 6783961 (2004-08-01), Edwards et al.
patent: 6821724 (2004-11-01), Mittman et al.
patent: WO 95/30758 (1995-11-01), None
patent: WO 99/14375 (1999-03-01), None
patent: WO 99/58559 (1999-11-01), None
patent: WO 00/58473 (2000-10-01), None
patent: WO 01 07471 (2001-02-01), None
patent: WO 01/07471 (2001-02-01), None
patent: WO 01/07471 (2001-02-01), None
patent: WO 01/60855 (2001-08-01), None
patent: WO 01/64834 (2001-09-01), None
Bowie et al (Science, 1990, 247:1306-1310).
Nakatsu et al (Journal of Biological Chemistry, 2000, 45: 34931-34937).
Hirosawa et al (DNA research, 1999, 6:329-336).
Nakatsu et al (J of Biological Chemistry, 2000, 275:34931-34937).
Patel et al (Biotechnology Letters, Apr. 2002, 24:657-662).
Score Search Results for Application 10490550: See Result 5. pp. 1-14.
Boehringer Mannheim Biochemicals, 1994 Catalog, p. 93.
Seo S. et al. Regulation of Histone Acetylation and Transcription by INHAT, a Human Cellular Complex Containing the Set Oncoprotein, Cell (Jan. 12, 2001), vol. 104, No. 1, p. 119-130.
Altschul, S. et al. J. Mol Biol. 215: 403-410 (1990); “Basic Local Alignment Search Tool”.
Avantaggiati, M.L. et al. Cell 89:1175-1184 (1997); “Recruitment of p300/CBP in p53-Dependent Signal Pathways”.
Borrow, J. et al., Nature Genet., 14:33-41 (1996); “The Translocation t(8:16)(p11;p13) of Acute Myeloid Leukaemia Fuses a Putative Acetyltransferase To The CREB-Binding Protein”.
Chaffanet, M. et al., Genes Chromosomes Cancer, 28:138-144 (2000): “MOZ Is Fused to p300 in An Acute Monocytic Leukemia With t(8:22)”.
Elbashir SM., et al. Nature, 411: 494-498 (2001); “Duplexes of 21-Nucleotide RNAs Mediate RNA Interference in Cultured Mammalian Cells”.
Fan, S.J., et al. Cancer Res., 54: 5824-5830 (1994); “p53 Gene Mutations Are Associated With Decreased Sensitivity Of Human Lymphoma Cells to DNA Damaging Agents”.
Fujiwara, et al. Cancer Res., 54, 2287-2291 (1994); “Induction of Chemosensitivity in Human Lung Cancer Cells in Vivo by Adenovirus-mediated Transfer of the Wild-Type p53 Gene”.
Gayther, S.A. et al., Nature Genet., 24:300-303 (2000); “Mutations Truncating the EP300 Acetylase in Human Cancers”.
Ida, K. et al., Blood, 90:4699-4704 (1997); “Adenoviral E1A-Associated Protein p300 Is Involved in Acute Mayeloid Leukemia With t(11;22)(q23:q13)”.
Kitabayashi, I., et al., Leukemia, 15:89-94 (2001); “Fusion Of MOZ Histone Acetyltransferases in Acute Monocytic Leukemia With a t(8;22)(p11;q13) Chromosome Translocation”.
Laboratory Manual for Genetic Engineering, 3rdcompiled by M. Maturura, issued by Maruzen Co., Ltd. (1996), pp. 242-246.
Lill, N. L. et al. Nature 387:823-827 (1997); “Binding and Modulation Of p53 by p300/CBP Coactivators”.
Lowe, S.W., et al. Science 266: 807-810 (1994); “p53 Status And The Efficacy Of Cancer Therapy In Vivo”.
Lowe, S.W., et al. Cell 74: 954-967 (1993); “p53-Dependent Apoptosis Modulates The Cytotoxicity Of Anticancer Agents”.
Noda K. et al., “Gan to kagaku chlryou hou (Cancer and its chemical therapy)”, 21, 1633 (1994); “Etoposide 21”.
Ogawa I. et al., “Gan to kagaku chiryou hou (Cancer and its chemical therapy)”, 10, 2403 (1983); “VP-16-213 Phase I Study”.
Panagopoulos, I. et al., Hum. Mol. Genet., 10:395-404 (2001); “Fusion Of The MORF and CBP Genes in Acute Myeloid Leukemia With The t(10;16)(q22;p13)”.
Satake, N. et al., Genes Chromosomes Cancer, 20:60-63 (1997); “Novel MLL-CBP Fusion Transcript in Therapy-Related Chronic Myelomonocytic Leukemia With a t(11;16)(q23;p13) Chromosome Translocation”.
Scolnick, D.M. et al., Cancer Res., 57:3693-3696 (1997); “CREB-Binding Protein And p300/CBP-Associated Factor Are Transcriptional Coactivators Of The p53 Tumor Suppressor Protein”.
Shikama, N. et al., Mol. Cell, 4:365-376 (1999); “A Novel Cofactor For p300 That Regulates The p53 Response”.
Sobulo, O.M. et al., Proc. Natl. Acad. Sci. USA, 94:8732-8737 (1997); “MLL Is Fused to CBP, a Histone Acetyltransferase, In Therapy-Related Acute Myeloid Leukemia With a t(11;16)(q23;p13.3)”.
Taki, T. et al., Blood, 89:3945-3950 (1997);“The t(11;16)(q23;p13) Translocation in Myelodysplastic Syndrome Fuses the MLL Gene To The CBP Gene”.
Niitsu, Y et al., Molecular Medicine 35:1385-1395 (1998); “Cancer Gene Therapy”.
U.S. Appl. No. 10/522,277, Mizutani et al.
Baniahmad, A., et al., “A transferable silencing domain is present in the thyroid hormone receptor, in, the verbA oncongene product and in the retinoic acid receptor,” EMBO Journal, 11(3), 1015-23 (1992).
Baudino, T.A., et al., “Isolation and Characterization of a Novel Coactivator Protein, NCoA-62, Involved in Vitamin D-mediated Transcription,” J. Biol Chem 273(26), 16434-41 (1998).
Fondell, J.D., et al., “Unliganded thyroid hormone receptor inhibits formation of a functional preinitiation complex: implications for active repression,” Genes & Develop., 7(7), 1400-10 (1993).
Lamb, J.R., et al., “Tetratrico peptide repeat interactions: to TPR or not to TPR?,” Trends Biochem Sci 20(7), 257-9 (1995).
MacDonald, P.N., et al., “Vitamin D receptor and nuclear receptor coactivators: crucial interactions in vitamin D-mediated transcription,” Steroids 66(3-5), 171-6 (2001).
Hacia, J.G., et al “Determination of ancestral alleles for human single-nucleotide polymorphisms using high-density oligonucleotide arrays.” Nature Genetics (1999)22: 164.
Niles R.M. Nutrition 16(11-12), 1084-9 (2000).
Okuno, M. et al., Front Biosci 7. 204-18 (2002).
Smith et al. “The tetratricopeptide repeats of Ssn6 interact with the homeo domain of alpha 2,” Genes Dev. 9:2903-10. (1995).
Riecken E.O. and Rosewicz S. 10 Suppl 4, 197-200 (1999).
Schmutzler C. and Kohrle J. Tyroid 10(5), 393-406 (2000).
Tactics of SNP Gene Variation, by Kenichi Matsubara and Yosiyuki Sakaki, published by Nakayama Shoten, p. 128-135.
Yoshimichi, et al., “XAB2, a Novel Tetratricopeptide Repeat Protein Involved in Transcription-coupled DNA Repair and Transcription,” Journal Biological Chem., 275:34931-34937 (2000).
Zhang D. et. al., J, Cell Physiol 185(1), 1-20, (2000).
Zhang, K., et al., “Thecrooked neckgene ofDrosophilacontains a motif found in a family of yeast cell cycle genes,” Genes Dev 5(6), 1080-91 (1991).
Molecular Cloning 3rd Ed, Chapter 2, pp. 2.1.
Molecular Cloning 3rd Ed, Chapter 8, pp. 8.1.
Molecular Cloning 3rd Ed, Chapter 8, Protocol 8, pp. 8.46.
Altschul et al. J.Mol. Biol. 215:403.
Karlin and Altschul Proc. Natl. Acad. Sci. USA 87:2264.
Karlin and Altschul Proc. Natl. Acad. Sci. Proc. Natl. Acad. Sci. USA 90:5873.
Special Coordination Funds for Promoting Science and Technology “Research on Development of Fundamental Technology to Elucidate Genomic Dynamics,”(Primary Period: 1996 to 1998), Research Report, Research and Development Bureau, Science and Technology Agency, Sep. 1999.
Notification of Reasons for Refusal in Japanese Patent Application No. 2003-530851.

Affiliated with

Also associated with

Rating

P300 histone acetylase inhibitor does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with P300 histone acetylase inhibitor, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and P300 histone acetylase inhibitor will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4154459